US Stock MarketDetailed Quotes
OSTX OS Therapies
- 3.830
- +0.050+1.32%
Close Dec 24 13:00 ET
- 3.830
- 0.0000.00%
Post 17:01 ET
81.34MMarket Cap-10.94P/E (TTM)
4.459High3.630Low93.04KVolume4.080Open3.780Pre Close374.01KTurnover5.82%Turnover RatioLossP/E (Static)21.24MShares6.48052wk High-116.06P/B6.13MFloat Cap1.58052wk Low--Dividend TTM1.60MShs Float6.480Historical High--Div YieldTTM21.94%Amplitude1.580Historical Low4.019Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
OS Therapies Stock Forum
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...
No comment yet